PAM
PCRX icon

Paradigm Asset Management’s Pacira BioSciences PCRX Stock Holding History

Paradigm Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,900
Closed -$207K – 819
2016
Q1 		$207K Hold
3,900
– – 0.04% 307
2015
Q4 		$299K Sell
3,900
-36,300
-90% -$2.06M 0.05% 323
2015
Q3 		$1.65M Sell
40,200
-200
-0.5% -$12.3K 0.22% 140
2015
Q2 		$2.86M Hold
40,400
– – 0.32% 100
2015
Q1 		$3.59M Buy
40,400
+4,900
+14% +$497K 0.4% 79
2014
Q4 		$3.15M Sell
35,500
-100
-0.3% -$9.46K 0.41% 83
2014
Q3 		$3.45M Buy
+35,600
New +$3.46M 0.48% 77

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return